Tony has 25-plus years’ experience in the combined areas of business development and R&D. As a PhD virologist he worked first in the vaccine industry, leading research teams at Evans Biologicals and later Glaxo Animal Health Ltd that developed, registered and launched several novel vaccines.
Tony moved to British Technology Group (BTG) where he successfully licensed IP worldwide, chiefly in the vaccine area. He was a key member of the team that founded Peptide Therapeutics (purchased as Acambis by Sanofi in 2008 for £276 million) and was a member of the management team that prepared and completed a £122 million rights issue in 2000. Tony also brought IP ‘in’ and ‘out’ licensing skills to BioVex Ltd (purchased in 2011 by Amgen Inc in a deal worth up to $1 billion).
His marketing skills steered the company to ‘Fierce 15’ award recognition at the BIO Convention in 2006. Tony has served as NED to the West Midlands Enterprise Group. He is also an alumnus of the London Business School (Corporate Finance Evening Programme).
Tony serves as a Non-Executive Director to IPAV Ltd and is also Director of Business Development at Glide Technologies Ltd.